Trial Profile
An Open-label, Non-randomized, 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment With Belimumab 10 mg/kg in Systemic Lupus Erythematosus Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 16 Feb 2022 Results assessing impact of temporary withdrawal of intravenous belimumab in patients with systemic lupus erythematosus, published in the Arthritis Research and Therapy.
- 08 Jan 2019 Status changed from active, no longer recruiting to completed.
- 18 Sep 2017 Planned End Date changed from 23 Aug 2019 to 13 Dec 2018.